The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study
Open accessAbstract
Purpose: Twenty percent of patients with follicular lymphoma (FL) experience progression of disease (POD) within 2 years of initial chemoimmunotherapy. We analyzed data from the National LymphoCare Study to identify whether prognostic FL factors are associated with early POD and whether patients with early POD are at high risk for death. Patients and Methods: In total, 588 patients with stage 2 to 4 FL received first-line rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). Two groups were defined: patients with early POD 2 years or less after diagnosis and those without POD within 2 years, the reference group. An independent validation set, 147 patients with FL who received first-line R-CHOP, was analyzed for reproducibility. Results: Of 588 patients, 19% (n = 110) had early POD, 71% (n = 420) were in the reference group, 8% (n = 46) were lost to follow-up, and 2% (n = 12) died without POD less than 2 years after diagnosis. Five-year overall survival was lower in the early-POD group than in the reference group (50% v 90%). This trend was maintained after we adjusted for FL International Prognostic Index (hazard ratio, 6.44; 95% CI, 4.33 to 9.58). Results were similar for the validation set (FL International Prognostic Index–adjusted hazard ratio, 19.8). Conclusion: In patients with FL who received first-line R-CHOP, POD within 2 years after diagnosis was associated with poor outcomes and should be further validated as a standard end point of chemoimmunotherapy trials of untreated FL. This high-risk FL population warrants further study in directed prospective clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Predictive Model for Aggressive Non-Hodgkin's Lymphoma
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291402 · Cited by 4,949
Non-Parametric Estimation of a Multivariate Probability Density
Epanechnikov, V. A. (1969) · Theory of Probability & Its Applications · doi:10.1137/1114019 · Cited by 1,835
Rummel, M. J., Niederle, N., Maschmeyer, G., Banat, G. A., von Grünhagen, U., Losem, C., Kofahl-Krause, D., Heil, G., Welslau, M., Balser, C., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61763-2 · Cited by 1,510
Dave, S. S., Wright, G., Tan, B., Rosenwald, A., Gascoyne, R. D., Chan, W. C., Fisher, R. I., Braziel, R. M., Rimsza, L. M., Grogan, T. M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041869 · Cited by 1,418
Follicular lymphoma international prognostic index
Solal-Celigny, P. (2006) · Current Treatment Options in Oncology · doi:10.1007/s11864-006-0036-3 · Cited by 1,339
Salles, G., Seymour, J. F., Offner, F., López-Guillermo, A., Belada, D., Xerri, L., Feugier, P., Bouabdallah, R., Catalano, J. V., Brice, P., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62175-7 · Cited by 1,079
Marcus, R. (2005) · Blood · doi:10.1182/blood-2004-08-3175 · Cited by 967
Federico, M., Bellei, M., Marcheselli, L., Luminari, S., Lopez-Guillermo, A., Vitolo, U., Pro, B., Pileri, S., Pulsoni, A., Soubeyran, P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.3991 · Cited by 751
Sargent, D. J., Wieand, H. S., Haller, D. G., Gray, R., Benedetti, J. K., Buyse, M., Labianca, R., Seitz, J. F., O'Callaghan, C. J., Francini, G., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.6071 · Cited by 713
Flinn, I. W., van der Jagt, R., Kahl, B. S., Wood, P., Hawkins, T. E., MacDonald, D., Hertzberg, M., Kwan, Y.-L., Simpson, D., Craig, M., et al. (2014) · Blood · doi:10.1182/blood-2013-11-531327 · Cited by 643
Follicular Lymphoma International Prognostic Index
Solal-Celigny, P. (2004) · Blood · doi:10.1182/blood-2003-12-4434 · Cited by 626
Marcus, R., Imrie, K., Solal-Celigny, P., Catalano, J. V., Dmoszynska, A., Raposo, J. C., Offner, F. C., Gomez-Codina, J., Belch, A., Cunningham, D., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.5376 · Cited by 594
Zelenetz, A. D., Abramson, J. S., Advani, R. H., Andreadis, C. B., Bartlett, N., Bellam, N., Byrd, J. C., Czuczman, M. S., Fayad, L. E., Glenn, M. J., et al. (2011) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2011.0046 · Cited by 454
Self-citationMaurer, M. J., Ghesquières, H., Jais, J.-P., Witzig, T. E., Haioun, C., Thompson, C. A., Delarue, R., Micallef, I. N., Peyrade, F., Macon, W. R., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.51.5866 · Cited by 411
Self-citationNew Treatment Options Have Changed the Survival of Patients With Follicular Lymphoma
Fisher, R. I., LeBlanc, M., Press, O. W., Maloney, D. G., Unger, J. M., & Miller, T. P. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.1674 · Cited by 375
Johnson, P. W., Rohatiner, A. Z., Whelan, J. S., Price, C. G., Love, S., Lim, J., Matthews, J., Norton, A. J., Amess, J. A., & Lister, T. A. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.1.140 · Cited by 337
Link, B. K., Maurer, M. J., Nowakowski, G. S., Ansell, S. M., Macon, W. R., Syrbu, S. I., Slager, S. L., Thompson, C. A., Inwards, D. J., Johnston, P. B., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.3990 · Cited by 335
Self-citationWildiers, H., Mauer, M., Pallis, A., Hurria, A., Mohile, S. G., Luciani, A., Curigliano, G., Extermann, M., Lichtman, S. M., Ballman, K., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.6125 · Cited by 322
Follicular Lymphoma in the United States: First Report of the National LymphoCare Study
Friedberg, J. W., Taylor, M. D., Cerhan, J. R., Flowers, C. R., Dillon, H., Farber, C. M., Rogers, E. S., Hainsworth, J. D., Wong, E. K., Vose, J. M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.1495 · Cited by 294
Self-citationFederico, M., Luminari, S., Dondi, A., Tucci, A., Vitolo, U., Rigacci, L., Di Raimondo, F., Carella, A. M., Pulsoni, A., Merli, F., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.0866 · Cited by 264
Tan, D. C. L., Horning, S. J., Hoppe, R. T., Levy, R., Rosenberg, S. A., Sigal, B. M., Warnke, R. A., Natkunam, Y., Han, S. S., Yuen, A. R., et al. (2013) · Blood · doi:10.1182/blood-2013-03-491514 · Cited by 262
Press, O. W., Unger, J. M., Rimsza, L. M., Friedberg, J. W., LeBlanc, M., Czuczman, M. S., Kaminski, M., Braziel, R. M., Spier, C., Gopal, A. K., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.4101 · Cited by 174
Self-citationCheung, K.-J. J., Shah, S. P., Steidl, C., Johnson, N. A., Relander, T., Telenius, A., Lai, B., Murphy, K. P., Lam, W. L., Al-Tourah, A. J., et al. (2008) · Blood · doi:10.1182/blood-2008-02-140616 · Cited by 138
O’Shea, D., Ó’Riain, C., Taylor, C., Waters, R., Carlotti, E., MacDougall, F., Gribben, J. G., Rosenwald, A., Ott, G., Rimsza, L. M., et al. (2008) · Blood · doi:10.1182/blood-2008-05-154013 · Cited by 130
Paolettí, X., Oba, K., Bang, Y., Bleiberg, H., Boku, N., Bouché, O., Catalano, P. J., Fuse, N., Michiels, S., Moehler, M. H., et al. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt269 · Cited by 90
LaCasce, A. S., Kho, M. E., Friedberg, J. W., Niland, J. C., Abel, G. A., Rodriguez, M. A., Czuczman, M. S., Millenson, M. M., Zelenetz, A. D., & Weeks, J. C. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.4061 · Cited by 82
Self-citationRobinson, S. P., Canals, C., Luang, J. J., Tilly, H., Crawley, C. R., Cahn, J.-Y. Y., Pohlreich, D., Gouill, S. L., Gilleece, M. H., Milpied, N. J., et al. (2013) · Bone Marrow Transplantation · doi:10.1038/bmt.2013.83 · Cited by 77
Saad, E. D., & Buyse, M. E. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.6359 · Cited by 71
Bachy, E., Brice, P., Delarue, R., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.7819 · Cited by 68
Dissecting follicular lymphoma: high versus low risk
Smith, S. M. (2013) · Hematology · doi:10.1182/asheducation-2013.1.561 · Cited by 22
Cited by
Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
Schuster, S. J., Svoboda, J., Chong, E. A., Nasta, S. D., Mato, A. R., Anak, Ö., Brogdon, J. L., Pruteanu-Malinici, I., Bhoj, V., Landsburg, D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708566 · Cited by 1,860
Armitage, J. O., Gascoyne, R. D., Lunning, M. A., & Cavalli, F. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32407-2 · Cited by 1,176
CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma
Advani, R., Flinn, I., Popplewell, L., Forero, A., Bartlett, N. L., Ghosh, N., Kline, J., Roschewski, M., LaCasce, A., Collins, G. P., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1807315 · Cited by 1,126
Obinutuzumab for the First-Line Treatment of Follicular Lymphoma
Marcus, R., Davies, A., Ando, K., Klapper, W., Opat, S., Owen, C., Phillips, E., Sangha, R., Schlag, R., Seymour, J. F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614598 · Cited by 800
Dreyling, M., Campo, E., Hermine, O., Jerkeman, M., Le Gouill, S., Rule, S., Shpilberg, O., Walewski, J., & Ladetto, M. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx223 · Cited by 741
Metadata
- Authors
- Casulo, C., Byrtek, M., Dawson, K. L., Zhou, X., Farber, C. M., Flowers, C. R., Hainsworth, J. D., Maurer, M. J., Cerhan, J. R., Link, B. K., Zelenetz, A. D., & Friedberg, J. W.
- Venue
- Journal of Clinical Oncology
- Published
- 2015-08-10
- Volume
- 33
- Issue
- 23
- Pages
- 2516-2522
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2160093471
- Cited by
- 850
- References
- 30
- FWCI
- 41.53
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.